-
PB02-04 clinical activity of cabozantinib in patients with advanced hepatocellular carcinoma previously treated with anti-VEGF and immuno-oncology therapy: subgroup analysis from the phase 3 CELESTIAL trial
-
J.
Cheon,
C.
Yoo,
J.
Hong,
Han
Kim,
Daewon
Lee,
Myung
Lee,
J.
Kim,
Ilhwan
Kim,
Sang-Bo
Oh,
J.
Hwang,
H.
Chon,
Ho
Lim
(2021)
Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma
Liver International, 42
-
(
BruixJ
ChengA-L
MeinhardtG
, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol
2017; 67: 999–1008.28687477)
BruixJ
ChengA-L
MeinhardtG
, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol
2017; 67: 999–1008.28687477
BruixJ
ChengA-L
MeinhardtG
, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol
2017; 67: 999–1008.28687477,
BruixJ
ChengA-L
MeinhardtG
, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol
2017; 67: 999–1008.28687477
-
R.
Kelley,
T.
Meyer,
L.
Rimassa,
P.
Merle,
Joong-Won
Park,
T.
Yau,
S.
Chan,
J.
Blanc,
V.
Tam,
A.
Tran,
V.
Dadduzio,
D.
Markby,
R.
Kaldate,
A.
Cheng,
A.
El-Khoueiry,
G.
Abou-Alfa
(2020)
Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
Clinical Cancer Research, 26
-
(
ZhuAX
KangYK
YenCJ
, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol
2019; 20: 282–296.30665869)
ZhuAX
KangYK
YenCJ
, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol
2019; 20: 282–296.30665869
ZhuAX
KangYK
YenCJ
, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol
2019; 20: 282–296.30665869,
ZhuAX
KangYK
YenCJ
, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol
2019; 20: 282–296.30665869
-
M.
Teufel,
H.
Seidel,
K.
Köchert,
G.
Meinhardt,
R.
Finn,
J.
Llovet,
J.
Bruix
(2019)
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.
Gastroenterology, 156 6
-
F.
Yakes,
Jason
Chen,
Jenny
Tan,
K.
Yamaguchi,
Yongchang
Shi,
P.
Yu,
Fawn
Qian,
Felix
Chu,
F.
Bentzien,
B.
Cancilla,
Jessica
Orf,
A.
You,
A.
Laird,
S.
Engst,
Lillian
Lee,
Justin
Lesch,
Y.
Chou,
A.
Joly
(2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
Molecular Cancer Therapeutics, 10
-
A.
Vogel,
C.
Frenette,
M.
Sung,
B.
Daniele,
A.
Baron,
S.
Chan,
J.
Blanc,
T.
Tamai,
M.
Ren,
H.
Lim,
D.
Palmer,
Y.
Takami,
M.
Kudo
(2021)
Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma
Liver Cancer, 10
-
(
VogelA
FrenetteC
SungM
, et al. Baseline liver function and subsequent outcomes in the phase 3 REFLECT study of patients with unresectable hepatocellular carcinoma. Liver Cancer
2021; 10: 510–521.34721512)
VogelA
FrenetteC
SungM
, et al. Baseline liver function and subsequent outcomes in the phase 3 REFLECT study of patients with unresectable hepatocellular carcinoma. Liver Cancer
2021; 10: 510–521.34721512
VogelA
FrenetteC
SungM
, et al. Baseline liver function and subsequent outcomes in the phase 3 REFLECT study of patients with unresectable hepatocellular carcinoma. Liver Cancer
2021; 10: 510–521.34721512,
VogelA
FrenetteC
SungM
, et al. Baseline liver function and subsequent outcomes in the phase 3 REFLECT study of patients with unresectable hepatocellular carcinoma. Liver Cancer
2021; 10: 510–521.34721512
-
G.
Abou-Alfa,
S.
Chan,
M.
Kudo,
G.
Lau,
R.
Kelley,
J.
Furuse,
W.
Sukeepaisarnjaroen,
Yoon-Koo
Kang,
T.
Dao,
E.
Toni,
L.
Rimassa,
V.
Breder,
A.
Vasilyev,
A.
Heurgue,
V.
Tam,
K.
Mody,
S.
Thungappa,
P.
He,
A.
Negro,
B.
Sangro
(2022)
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
Journal of Clinical Oncology
-
(
YakesFM
ChenJ
TanJ
, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther
2011; 10: 2298–2308.21926191)
YakesFM
ChenJ
TanJ
, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther
2011; 10: 2298–2308.21926191
YakesFM
ChenJ
TanJ
, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther
2011; 10: 2298–2308.21926191,
YakesFM
ChenJ
TanJ
, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther
2011; 10: 2298–2308.21926191
-
(
CheonJ
YooC
HongJY
, et al. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. Liver Int
2022; 42: 674–681.34792284)
CheonJ
YooC
HongJY
, et al. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. Liver Int
2022; 42: 674–681.34792284
CheonJ
YooC
HongJY
, et al. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. Liver Int
2022; 42: 674–681.34792284,
CheonJ
YooC
HongJY
, et al. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. Liver Int
2022; 42: 674–681.34792284
-
L.
Rimassa,
R.
Kelley,
T.
Meyer,
B.
Ryoo,
P.
Merle,
Joong-Won
Park,
J.
Blanc,
Ho
Lim,
A.
Tran,
Yi-Wah
Chan,
P.
McAdam,
E.
Wang,
A.
Cheng,
A.
El-Khoueiry,
G.
Abou-Alfa
(2021)
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma
Liver Cancer, 11
-
R.
Finn,
B.
Ryoo,
P.
Merle,
M.
Kudo,
M.
Bouattour,
Ho
Lim,
V.
Breder,
J.
Edeline,
Y.
Chao,
S.
Ogasawara,
T.
Yau,
M.
Garrido,
S.
Chan,
J.
Knox,
B.
Daniele,
S.
Ebbinghaus,
E.
Chen,
A.
Siegel,
A.
Zhu,
A.
Cheng
(2019)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
-
(
PersoneniN
BozzarelliS
PressianiT
, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol
2012; 57: 101–107.22414760)
PersoneniN
BozzarelliS
PressianiT
, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol
2012; 57: 101–107.22414760
PersoneniN
BozzarelliS
PressianiT
, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol
2012; 57: 101–107.22414760,
PersoneniN
BozzarelliS
PressianiT
, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol
2012; 57: 101–107.22414760
-
(
OgasawaraS
KorokiK
KanzakiH
, et al. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int. Epub ahead of print 15 November 2021. DOI: 10.1111/liv.15101.)
OgasawaraS
KorokiK
KanzakiH
, et al. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int. Epub ahead of print 15 November 2021. DOI: 10.1111/liv.15101.
OgasawaraS
KorokiK
KanzakiH
, et al. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int. Epub ahead of print 15 November 2021. DOI: 10.1111/liv.15101.,
OgasawaraS
KorokiK
KanzakiH
, et al. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int. Epub ahead of print 15 November 2021. DOI: 10.1111/liv.15101.
-
Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial
-
C.
Fitzmaurice,
Christine
Allen,
Ryan
Barber,
L.
Barregard,
Z.
Bhutta,
H.
Brenner,
D.
Dicker,
Odgerel
Chimed-Orchir,
R.
Dandona,
L.
Dandona,
T.
Fleming,
M.
Forouzanfar,
Jamie
Hancock,
Roderick
Hay,
Rachel
Hunter-Merrill,
Chantal
Huynh,
H.
Hosgood,
C.
Johnson,
J.
Jonas,
J.
Khubchandani,
G.
Kumar,
Michael
Kutz,
Q.
Lan,
H.
Larson,
Xiaofeng
Liang,
Stephen
Lim,
Alan
Lopez,
Michael
MacIntyre,
L.
Marczak,
N.
Marquez,
A.
Mokdad,
Christine
Pinho,
F.
Pourmalek,
J.
Salomon,
J.
Sanabria,
Logan
Sandar,
B.
Sartorius,
S.
Schwartz,
K.
Shackelford,
K.
Shibuya,
J.
Stanaway,
C.
Steiner,
Jiandong
Sun,
Ken
Takahashi,
S.
Vollset,
T.
Vos,
Joseph
Wagner,
Haidong
Wang,
R.
Westerman,
H.
Zeeb,
Leo
Zoeckler,
F.
Abd-Allah,
M.
Ahmed,
S.
Alabed,
N.
Alam,
S.
Aldhahri,
Girma
Alem,
Mulubirhan
Alemayohu,
R.
Ali,
Rajaa
Al-Raddadi,
Azmeraw
Amare,
Y.
Amoako,
A.
Artaman,
H.
Asayesh,
N.
Atnafu,
A.
Awasthi,
H.
Saleem,
A.
Barać,
Neeraj
Bedi,
I.
Benseñor,
A.
Berhane,
E.
Bernabé,
B.
Betsu,
A.
Binagwaho,
D.
Boneya,
Ismael
Campos-Nonato,
C.
Castañeda-Orjuela,
F.
Catalá-López,
P.
Chiang,
C.
Chibueze,
Abdulaal
Chitheer,
J.
Choi,
B.
Cowie,
S.
Damtew,
J.
Neves,
S.
Dey,
S.
Dharmaratne,
P.
Dhillon,
E.
Ding,
T.
Driscoll,
D.
Ekwueme,
A.
Endries,
M.
Farvid,
F.
Farzadfar,
João
Fernandes,
F.
Fischer,
Tsegaye
G/hiwot,
A.
Gebru,
S.
Gopalani,
A.
Hailu,
M.
Horino,
N.
Horita,
A.
Husseini,
I.
Huybrechts,
M.
Inoue,
F.
Islami,
M.
Jakovljevic,
S.
James,
Mehdi
Javanbakht,
S.
Jee,
A.
Kasaeian,
Muktar
Kedir,
Y.
Khader,
Y.
Khang,
Daniel
Kim,
J.
Leigh,
S.
Linn,
R.
Lunevicius,
Hassan
Razek,
R.
Malekzadeh,
D.
Malta,
W.
Marcenes,
D.
Markos,
Y.
Melaku,
K.
Meles,
W.
Mendoza,
Desalegn
Mengiste,
T.
Meretoja,
T.
Miller,
K.
Mohammad,
A.
Mohammadi,
S.
Mohammed,
M.
Moradi-Lakeh,
G.
Nagel,
D.
Nand,
Q.
Nguyen,
Sandra
Nolte,
F.
Ogbo,
K.
Oladimeji,
Eyal
Oren,
Mahesh
Pa,
Eun‐Kee
Park,
David
Pereira,
D.
Plass,
M.
Qorbani,
A.
Radfar,
Anwar
Rafay,
Mahfuzar
Rahman,
S.
Rana,
K.
Søreide,
Maheswar
Satpathy,
M.
Sawhney,
S.
Sepanlou,
M.
Shaikh,
Jun
She,
I.
Shiue,
H.
Shore,
M.
Shrime,
S.
So,
S.
Soneji,
V.
Stathopoulou,
K.
Stroumpoulis,
M.
Sufiyan,
Bryan
Sykes,
R.
Tabarés-Seisdedos,
Fentaw
Tadese,
B.
Tedla,
G.
Tessema,
J.
Thakur,
B.
Tran,
K.
Ukwaja,
B.
Uzochukwu,
V.
Vlassov,
E.
Weiderpass,
Mamo
Terefe,
Henock
Yebyo,
H.
Yimam,
N.
Yonemoto,
M.
Younis,
Chuanhua
Yu,
Z.
Zaidi,
M.
Zaki,
Z.
Zenebe,
C.
Murray,
M.
Naghavi
(2017)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study
JAMA Oncology, 3
-
J.
Trojan,
P.
Mollon,
B.
Daniele,
F.
Marteau,
L.
Martín,
Yuxin
Li,
Qing
Xu,
F.
Piscaglia,
R.
Zaucha,
D.
Sarker,
Ho
Lim,
M.
Venerito
(2021)
Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison
Advances in Therapy, 38
-
G.
Abou-Alfa,
T.
Meyer,
A.
Cheng,
A.
El-Khoueiry,
L.
Rimassa,
B.
Ryoo,
I.
Çiçin,
P.
Merle,
Yen-Chang
Chen,
Joong-Won
Park,
J.
Blanc,
L.
Bolondi,
H.
Klümpen,
S.
Chan,
V.
Zagonel,
T.
Pressiani,
M.
Ryu,
A.
Venook,
C.
Hessel,
A.
Borgman-Hagey,
G.
Schwab,
R.
Kelley
(2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
The New England Journal of Medicine, 379
-
A.
El-Khoueiry,
B.
Sangro,
T.
Yau,
T.
Crocenzi,
M.
Kudo,
Chiun
Hsu,
Tae-You
Kim,
S.
Choo,
J.
Trojan,
T.
Welling,
T.
Meyer,
Yoon-Koo
Kang,
W.
Yeo,
A.
Chopra,
Jeffrey
Anderson,
C.
Cruz,
Lixin
Lang,
J.
Neely,
Hao
Tang,
H.
Dastani,
I.
Melero
(2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
The Lancet, 389
-
(
RimassaL
DanesiR
PressianiT
, et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev
2019; 77: 20–28.31195212)
RimassaL
DanesiR
PressianiT
, et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev
2019; 77: 20–28.31195212
RimassaL
DanesiR
PressianiT
, et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev
2019; 77: 20–28.31195212,
RimassaL
DanesiR
PressianiT
, et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev
2019; 77: 20–28.31195212
-
R.
Kelley,
T.
Yau,
A.
Cheng,
A.
Kaseb,
S.
Qin,
A.
Zhu,
S.
Chan,
W.
Sukeepaisarnjaroen,
V.
Breder,
G.
Verset,
E.
Gane,
I.
Borbath,
J.
Rangel,
P.
Merle,
F.
Benzaghou,
K.
Banerjee,
S.
Hazra,
J.
Fawcett,
L.
Rimassa
(2021)
VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
Annals of Oncology
-
F.
Tovoli,
V.
Dadduzio,
S.
Lorenzo,
L.
Rimassa,
G.
Masi,
M.
Iavarone,
F.
Marra,
I.
Garajová,
M.
Brizzi,
B.
Daniele,
F.
Trevisani,
C.
Messina,
Francesco
Clemente,
S.
Pini,
G.
Cabibbo,
A.
Granito,
M.
Rizzato,
V.
Zagonel,
G.
Brandi,
T.
Pressiani,
P.
Federico,
C.
Vivaldi,
I.
Bergna,
C.
Campani,
F.
Piscaglia
(2021)
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
Liver Cancer, 10
-
(
TrojanJ
MollonP
DanieleB
, et al. Comparative efficacy of cabozantinib and ramucirumab after sorafenib for patients with hepatocellular carcinoma and alpha-fetoprotein ⩾ 400 ng/ml: a matching-adjusted indirect comparison. Adv Ther
2021; 38: 2472–2490.33822328)
TrojanJ
MollonP
DanieleB
, et al. Comparative efficacy of cabozantinib and ramucirumab after sorafenib for patients with hepatocellular carcinoma and alpha-fetoprotein ⩾ 400 ng/ml: a matching-adjusted indirect comparison. Adv Ther
2021; 38: 2472–2490.33822328
TrojanJ
MollonP
DanieleB
, et al. Comparative efficacy of cabozantinib and ramucirumab after sorafenib for patients with hepatocellular carcinoma and alpha-fetoprotein ⩾ 400 ng/ml: a matching-adjusted indirect comparison. Adv Ther
2021; 38: 2472–2490.33822328,
TrojanJ
MollonP
DanieleB
, et al. Comparative efficacy of cabozantinib and ramucirumab after sorafenib for patients with hepatocellular carcinoma and alpha-fetoprotein ⩾ 400 ng/ml: a matching-adjusted indirect comparison. Adv Ther
2021; 38: 2472–2490.33822328
-
F.
Finkelmeier,
B.
Scheiner,
C.
Leyh,
J.
Best,
T.
Fründt,
C.
Czauderna,
Alica
Beutel,
D.
Bettinger,
J.
Weiss,
T.
Meischl,
F.
Kuetting,
D.
Waldschmidt,
P.
Radu,
M.
Schultheiss,
K.
Peiffer,
T.
Ettrich,
A.
Weinmann,
H.
Wege,
M.
Venerito,
J.
Dufour,
C.
Lange,
M.
Pinter,
O.
Waidmann
(2021)
Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort
Liver Cancer, 10
-
J.
Bruix,
A.
Cheng,
G.
Meinhardt,
K.
Nakajima,
Yoriko
Sanctis,
J.
Llovet
(2017)
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Journal of hepatology, 67 5
-
J.
Bruix,
S.
Qin,
P.
Merle,
A.
Granito,
Yi‐Hsiang
Huang,
G.
Bodoky,
M.
Pracht,
O.
Yokosuka,
O.
Rosmorduc,
V.
Breder,
R.
Gérolami,
G.
Masi,
P.
Ross,
T.
Song,
J.
Bronowicki,
I.
Ollivier-Hourmand,
M.
Kudo,
A.
Cheng,
J.
Llovet,
R.
Finn,
M.
Leberre,
A.
Baumhauer,
G.
Meinhardt,
G.
Han
(2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet, 389
-
(
TeufelM
SeidelH
KöchertK
, et al. Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology
2019; 156: 1731–1741.30738047)
TeufelM
SeidelH
KöchertK
, et al. Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology
2019; 156: 1731–1741.30738047
TeufelM
SeidelH
KöchertK
, et al. Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology
2019; 156: 1731–1741.30738047,
TeufelM
SeidelH
KöchertK
, et al. Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology
2019; 156: 1731–1741.30738047
-
S.
Ogasawara,
K.
Koroki,
Hiroaki
Kanzaki,
Kazufumi
Kobayashi,
Soichiro
Kiyono,
Masato
Nakamura,
Naoya
Kanogawa,
Tomoko
Saito,
T.
Kondo,
R.
Nakagawa,
S.
Nakamoto,
R.
Muroyama,
T.
Chiba,
Naoya
Kato
(2021)
Changes in therapeutic options for hepatocellular carcinoma in Asia
Liver International, 42
-
R.
Finn,
S.
Qin,
K.
Han,
F.
Piscaglia,
A.
Baron,
Joong-Won
Park,
G.
Han,
J.
Jassem,
Jean
Blanc,
A.
Vogel,
D.
Komov,
T.
Evans,
C.
Lopez,
C.
Dutcus,
M.
Guo,
Kenichi
Saito,
S.
Kraljevic,
T.
Tamai,
M.
Ren,
A.
Cheng
(2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
The Lancet, 391
-
(
TovoliF
DadduzioV
De LorenzoS
, et al. Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma. Liver Cancer
2021; 10: 370–379.34414124)
TovoliF
DadduzioV
De LorenzoS
, et al. Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma. Liver Cancer
2021; 10: 370–379.34414124
TovoliF
DadduzioV
De LorenzoS
, et al. Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma. Liver Cancer
2021; 10: 370–379.34414124,
TovoliF
DadduzioV
De LorenzoS
, et al. Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma. Liver Cancer
2021; 10: 370–379.34414124
-
(
YooC
ByeonS
BangY
, et al. Regorafenib in previously treated advanced hepatocellular carcinoma: impact of prior immunotherapy and adverse events. Liver Int
2020; 40: 2263–2271.32449588)
YooC
ByeonS
BangY
, et al. Regorafenib in previously treated advanced hepatocellular carcinoma: impact of prior immunotherapy and adverse events. Liver Int
2020; 40: 2263–2271.32449588
YooC
ByeonS
BangY
, et al. Regorafenib in previously treated advanced hepatocellular carcinoma: impact of prior immunotherapy and adverse events. Liver Int
2020; 40: 2263–2271.32449588,
YooC
ByeonS
BangY
, et al. Regorafenib in previously treated advanced hepatocellular carcinoma: impact of prior immunotherapy and adverse events. Liver Int
2020; 40: 2263–2271.32449588
-
(
KelleyRK
MollonP
BlancJF
, et al. Comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma. Adv Ther
2020; 37: 2678–2695.32424805)
KelleyRK
MollonP
BlancJF
, et al. Comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma. Adv Ther
2020; 37: 2678–2695.32424805
KelleyRK
MollonP
BlancJF
, et al. Comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma. Adv Ther
2020; 37: 2678–2695.32424805,
KelleyRK
MollonP
BlancJF
, et al. Comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma. Adv Ther
2020; 37: 2678–2695.32424805
-
Hyung-Don
Kim,
Y.
Bang,
Myung
Lee,
J.
Kim,
Jeehyoung
Kim,
H.
Chon,
B.
Kang,
Myoungjoo
Kang,
Ilhwan
Kim,
J.
Cheon,
J.
Hwang,
J.
Kang,
S.
Byeon,
J.
Hong,
B.
Ryoo,
Ho
Lim,
C.
Yoo
(2020)
Regorafenib in patients with advanced Child‐Pugh B hepatocellular carcinoma: A multicentre retrospective study
Liver International, 40
-
R.
Finn,
S.
Qin,
M.
Ikeda,
P.
Galle,
M.
Ducreux,
Tae-You
Kim,
M.
Kudo,
V.
Breder,
P.
Merle,
A.
Kaseb,
Daneng
Li,
W.
Verret,
Derek-Zhen
Xu,
S.
Hernandez,
Juan
Liu,
Chen
Huang,
S.
Mulla,
Yulei
Wang,
Ho
Lim,
A.
Zhu,
A.
Cheng
(2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
The New England journal of medicine, 382 20
-
(
Casadei-GardiniA
RimassaL
RiminiM
, et al. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. J Cancer Res Clin Oncol
2021; 147: 3665–3671.33745079)
Casadei-GardiniA
RimassaL
RiminiM
, et al. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. J Cancer Res Clin Oncol
2021; 147: 3665–3671.33745079
Casadei-GardiniA
RimassaL
RiminiM
, et al. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. J Cancer Res Clin Oncol
2021; 147: 3665–3671.33745079,
Casadei-GardiniA
RimassaL
RiminiM
, et al. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. J Cancer Res Clin Oncol
2021; 147: 3665–3671.33745079
-
(
KudoM
FinnRS
QinS
, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet
2018; 391: 1163–1173.29433850)
KudoM
FinnRS
QinS
, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet
2018; 391: 1163–1173.29433850
KudoM
FinnRS
QinS
, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet
2018; 391: 1163–1173.29433850,
KudoM
FinnRS
QinS
, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet
2018; 391: 1163–1173.29433850
-
(
MarreroJA
KudoM
VenookAP
, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. J Hepatol
2016; 65: 1140–1147.27469901)
MarreroJA
KudoM
VenookAP
, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. J Hepatol
2016; 65: 1140–1147.27469901
MarreroJA
KudoM
VenookAP
, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. J Hepatol
2016; 65: 1140–1147.27469901,
MarreroJA
KudoM
VenookAP
, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. J Hepatol
2016; 65: 1140–1147.27469901
-
L.
Rimassa,
R.
Danesi,
T.
Pressiani,
P.
Merle
(2019)
Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma.
Cancer treatment reviews, 77
-
(
FinkelmeierF
ScheinerB
LeyhC
, et al. Cabozantinib in advanced hepatocellular carcinoma: efficacy and safety data from an International Multicenter Real-Life Cohort. Liver Cancer
2021; 10: 360–369.34414123)
FinkelmeierF
ScheinerB
LeyhC
, et al. Cabozantinib in advanced hepatocellular carcinoma: efficacy and safety data from an International Multicenter Real-Life Cohort. Liver Cancer
2021; 10: 360–369.34414123
FinkelmeierF
ScheinerB
LeyhC
, et al. Cabozantinib in advanced hepatocellular carcinoma: efficacy and safety data from an International Multicenter Real-Life Cohort. Liver Cancer
2021; 10: 360–369.34414123,
FinkelmeierF
ScheinerB
LeyhC
, et al. Cabozantinib in advanced hepatocellular carcinoma: efficacy and safety data from an International Multicenter Real-Life Cohort. Liver Cancer
2021; 10: 360–369.34414123
-
Andrea
Tsoris,
C.
Marlar
(2019)
Use Of The Child Pugh Score In Liver Disease
-
P.
Johnson,
S.
Berhane,
Chiaki
Kagebayashi,
S.
Satomura,
M.
Teng,
H.
Reeves,
J.
O’Beirne,
R.
Fox,
A.
Skowrońska,
D.
Palmer,
W.
Yeo,
F.
Mo,
P.
Lai,
M.
Iñarrairaegui,
S.
Chan,
B.
Sangro,
R.
Miksad,
T.
Tada,
T.
Kumada,
H.
Toyoda
(2015)
Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 6
-
A.
Zhu,
Yoon-Koo
Kang,
C.
Yen,
R.
Finn,
P.
Galle,
J.
Llovet,
E.
Assenat,
G.
Brandi,
M.
Pracht,
Ho
Lim,
K.
Rau,
K.
Motomura,
I.
Ohno,
P.
Merle,
B.
Daniele,
D.
Shin,
G.
Gerken,
C.
Borg,
J.
Hiriart,
T.
Okusaka,
M.
Morimoto,
Y.
Hsu,
P.
Abada,
M.
Kudo
(2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet. Oncology, 20 2
-
R.
Kelley,
P.
Mollon,
J.
Blanc,
B.
Daniele,
T.
Yau,
A.
Cheng,
V.
Valcheva,
F.
Marteau,
I.
Guerra,
G.
Abou-Alfa
(2020)
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
Advances in Therapy, 37
-
(
FitzmauriceC
AllenC
BarberRM
, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol
2017; 3: 524–548.27918777)
FitzmauriceC
AllenC
BarberRM
, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol
2017; 3: 524–548.27918777
FitzmauriceC
AllenC
BarberRM
, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol
2017; 3: 524–548.27918777,
FitzmauriceC
AllenC
BarberRM
, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol
2017; 3: 524–548.27918777
-
(
El-KhoueiryAB
SangroB
YauT
, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet
2017; 389: 2492–2502.28434648)
El-KhoueiryAB
SangroB
YauT
, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet
2017; 389: 2492–2502.28434648
El-KhoueiryAB
SangroB
YauT
, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet
2017; 389: 2492–2502.28434648,
El-KhoueiryAB
SangroB
YauT
, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet
2017; 389: 2492–2502.28434648
-
T.
Yau,
Yoon-Koo
Kang,
Tae-You
Kim,
A.
El-Khoueiry,
A.
Santoro,
B.
Sangro,
I.
Melero,
M.
Kudo,
M.
Hou,
A.
Matilla,
F.
Tovoli,
J.
Knox,
A.
He,
B.
El-Rayes,
M.
Acosta-Rivera,
Ho
Lim,
J.
Neely,
Yun
Shen,
T.
Wisniewski,
Jeffrey
Anderson,
Chiun
Hsu
(2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
JAMA Oncology, 6
-
(
JohnsonPJ
BerhaneS
KagebayashiC
, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol
2015; 33: 550–558.25512453)
JohnsonPJ
BerhaneS
KagebayashiC
, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol
2015; 33: 550–558.25512453
JohnsonPJ
BerhaneS
KagebayashiC
, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol
2015; 33: 550–558.25512453,
JohnsonPJ
BerhaneS
KagebayashiC
, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol
2015; 33: 550–558.25512453
-
G.
Spinzi,
S.
Paggi
(2008)
Sorafenib in advanced hepatocellular carcinoma.
The New England journal of medicine, 359 23
-
(
KimH-D
BangY
LeeMA
, et al. Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: a multicentre retrospective study. Liver Int
2020; 40: 2544–2552.32563213)
KimH-D
BangY
LeeMA
, et al. Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: a multicentre retrospective study. Liver Int
2020; 40: 2544–2552.32563213
KimH-D
BangY
LeeMA
, et al. Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: a multicentre retrospective study. Liver Int
2020; 40: 2544–2552.32563213,
KimH-D
BangY
LeeMA
, et al. Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: a multicentre retrospective study. Liver Int
2020; 40: 2544–2552.32563213
-
Ramucirumab after sorafenib in patients with YH Bang
-
(
YauT
KangY-K
KimT-Y
, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol
2020; 6: e204564.)
YauT
KangY-K
KimT-Y
, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol
2020; 6: e204564.
YauT
KangY-K
KimT-Y
, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol
2020; 6: e204564.,
YauT
KangY-K
KimT-Y
, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol
2020; 6: e204564.
-
Changes in therapeutic options for hepatocellular carcinoma in Asia
-
N.
Personeni,
S.
Bozzarelli,
T.
Pressiani,
L.
Rimassa,
M.
Tronconi,
F.
Sclafani,
C.
Carnaghi,
V.
Pedicini,
L.
Giordano,
A.
Santoro
(2012)
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
Journal of hepatology, 57 1
-
(
ShenJ
ChanHL
WongGL
, et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol
2012; 56: 1363–1370.22314419)
ShenJ
ChanHL
WongGL
, et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol
2012; 56: 1363–1370.22314419
ShenJ
ChanHL
WongGL
, et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol
2012; 56: 1363–1370.22314419,
ShenJ
ChanHL
WongGL
, et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol
2012; 56: 1363–1370.22314419
-
A.
Casadei‐Gardini,
L.
Rimassa,
M.
Rimini,
C.
Yoo,
B.
Ryoo,
S.
Lonardi,
G.
Masi,
Hyung-Don
Kim,
C.
Vivaldi,
M.
Ryu,
M.
Rizzato,
F.
Salani,
Y.
Bang,
A.
Pellino,
S.
Catanese,
V.
Burgio,
S.
Cascinu,
A.
Cucchetti
(2021)
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis
Journal of Cancer Research and Clinical Oncology, 147
-
J.
Marrero,
M.
Kudo,
A.
Venook,
S.
Ye,
J.
Bronowicki,
Xiao-ping
Chen,
L.
Dagher,
J.
Furuse,
J.
Geschwind,
L.
Guevara,
C.
Papandreou,
T.
Takayama,
A.
Sanyal,
S.
Yoon,
K.
Nakajima,
R.
Lehr,
S.
Heldner,
R.
Lencioni
(2016)
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.
Journal of hepatology, 65 6
-
(
FinnRS
RyooBY
MerleP
, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol
2020; 38: 193–202.31790344)
FinnRS
RyooBY
MerleP
, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol
2020; 38: 193–202.31790344
FinnRS
RyooBY
MerleP
, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol
2020; 38: 193–202.31790344,
FinnRS
RyooBY
MerleP
, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol
2020; 38: 193–202.31790344
-
(
LlovetJM
RicciS
MazzaferroV
, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med
2008; 359: 378–390.18650514)
LlovetJM
RicciS
MazzaferroV
, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med
2008; 359: 378–390.18650514
LlovetJM
RicciS
MazzaferroV
, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med
2008; 359: 378–390.18650514,
LlovetJM
RicciS
MazzaferroV
, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med
2008; 359: 378–390.18650514
-
Jiayun
Shen,
H.
Chan,
G.
Wong,
P.
Choi,
A.
Chan,
H.
Chan,
A.
Chim,
D.
Yeung,
F.
Chan,
J.
Woo,
Jun
Yu,
W.
Chu,
V.
Wong
(2012)
Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers.
Journal of hepatology, 56 6
-
(
Abou-AlfaGK
ChanSL
KudoM
, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol
2022; 40(Suppl. 4): 379.)
Abou-AlfaGK
ChanSL
KudoM
, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol
2022; 40(Suppl. 4): 379.
Abou-AlfaGK
ChanSL
KudoM
, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol
2022; 40(Suppl. 4): 379.,
Abou-AlfaGK
ChanSL
KudoM
, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol
2022; 40(Suppl. 4): 379.
-
L.
Rimassa,
N.
Personeni,
C.
Czauderna,
F.
Foerster,
P.
Galle
(2020)
SYSTEMIC TREATMENT OF HCC IN SPECIAL POPULATIONS.
Journal of hepatology
-
C.
Yoo,
S.
Byeon,
Y.
Bang,
J.
Cheon,
J.
Kim,
Jeehyoung
Kim,
H.
Chon,
B.
Kang,
Myoungjoo
Kang,
Ilhwan
Kim,
J.
Hwang,
J.
Kang,
Myung
Lee,
J.
Hong,
Ho
Lim,
B.
Ryoo
(2020)
Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events
Liver International, 40
-
(
Abou-AlfaG
ChengA
SaletanS
, et al. PB02-04 clinical activity of cabozantinib in patients with advanced hepatocellular carcinoma previously treated with anti-VEGF and immuno-oncology therapy: subgroup analysis from the phase 3 CELESTIAL trial. In: Liver cancer summit-abstract book, Prague, 6–8
February
2020, p. 234. Prague: EASL.)
Abou-AlfaG
ChengA
SaletanS
, et al. PB02-04 clinical activity of cabozantinib in patients with advanced hepatocellular carcinoma previously treated with anti-VEGF and immuno-oncology therapy: subgroup analysis from the phase 3 CELESTIAL trial. In: Liver cancer summit-abstract book, Prague, 6–8
February
2020, p. 234. Prague: EASL.
Abou-AlfaG
ChengA
SaletanS
, et al. PB02-04 clinical activity of cabozantinib in patients with advanced hepatocellular carcinoma previously treated with anti-VEGF and immuno-oncology therapy: subgroup analysis from the phase 3 CELESTIAL trial. In: Liver cancer summit-abstract book, Prague, 6–8
February
2020, p. 234. Prague: EASL.,
Abou-AlfaG
ChengA
SaletanS
, et al. PB02-04 clinical activity of cabozantinib in patients with advanced hepatocellular carcinoma previously treated with anti-VEGF and immuno-oncology therapy: subgroup analysis from the phase 3 CELESTIAL trial. In: Liver cancer summit-abstract book, Prague, 6–8
February
2020, p. 234. Prague: EASL.
-
(
TsorisA
MarlarCA.
Use of the Child Pugh score in liver disease. Treasure Island, FL: StatPearls Publishing LLC, 2021.)
TsorisA
MarlarCA.
Use of the Child Pugh score in liver disease. Treasure Island, FL: StatPearls Publishing LLC, 2021.
TsorisA
MarlarCA.
Use of the Child Pugh score in liver disease. Treasure Island, FL: StatPearls Publishing LLC, 2021.,
TsorisA
MarlarCA.
Use of the Child Pugh score in liver disease. Treasure Island, FL: StatPearls Publishing LLC, 2021.